INTRODUCTION {#s1}
============

Breast cancer in 2012 was both the most common cancer worldwide, with 1.7 million new cases, and the leading cause of cancer-related deaths in women \[[@R1]\]. Breast cancer is commonly treated with chemotherapy either as an adjuvant systemic treatment after primary surgery or as neoadjuvant therapy before surgery. The neoadjuvant treatment attempts to reduce the tumour stage, with the goal of surgically resecting the mass. Currently, radiotherapy is commonly used after primary surgery to reduce the risk of recurrence \[[@R2]\]. However, patient response to treatment with chemotherapy and radiotherapy is quite variable \[[@R3]--[@R5]\]. Inter-patient variations in clinicopathologic characteristics such as clinical disease stage, lymph node status, and hormone receptor expression, could have a large influence on treatment outcomes. Increasing evidence suggests that drug-metabolizing enzymes may play an important role in inter-patient variations, which could affect treatment response and toxicities \[[@R6], [@R7]\].

Glutathione S-transferases (GSTs) are a superfamily of phase-II metabolic enzymes that play a key role in cellular resistance mechanisms \[[@R8]\]. GSTs detoxify cytotoxic agents by catalysing the reduction of these compounds through their conjugation with glutathione \[[@R9]\]. The *GSTP1* gene, a member of the *GST* family, is located on chromosome 11q13, which contains 7 exons and 6 introns. Genetic polymorphisms involving an adenine to guanine transition (rs1695) at codon 105 in exon 5 of the *GSTP1* gene results in amino acid substitution from isoleucine to valine (Ile→Val). This substitution decreases the enzymatic activity of glutathione-S-transferase P1 (GSTP1) and alters the pharmacokinetics of cyclophosphamide, which may influence treatment outcomes and toxicity for breast cancer \[[@R10]\].

Studies have investigated the associations of the *GSTP1* (A313G) gene polymorphism with treatment response, prognosis, and toxicities for breast cancer \[[@R11]--[@R41]\]. However, these findings failed to reach a consensus owing to a lack of data and inconsistencies in the results between these studies. Therefore, a systematic review and meta-analysis was conducted to evaluate the influence of the *GSTP1* (A313G) polymorphism on treatment outcomes and toxicities in patients with breast cancer.

MATERIALS AND METHODS {#s2}
=====================

Literature search and inclusion criteria {#s2_1}
----------------------------------------

PubMed, EMBASE, Cochrane Library, and China National Knowledge Infrastructure were searched for relevant studies up to August 29th, 2016, by using the following terms: "glutathione S-transferase," "glutathione S-transferase P1," "*GSTP1*," "breast cancer," "breast carcinoma," and "breast neoplasm." Studies were manually filtered without language restrictions. Additional studies were identified by screening references and relevant reviews.

Studies were included if they met the following criteria: (1) inclusion of patients who were treated for breast cancer; (2) evaluation of associations between *GSTP1* and treatment outcomes, as well as toxicities after radiotherapy and/or chemotherapy; (3) treatment outcomes including tumour response and overall survival (OS), with toxicities including all adverse effects; and (4) provision of adequate data for calculation of both odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs).

Data extraction {#s2_2}
---------------

The following items were gathered independently from all eligible studies by two investigators (JM and YL): first author\'s name, year of publication, country, number of patients, genotyping methods, median follow-up, treatment protocols, treatment outcomes, and toxicities. Any disagreements were resolved through discussion and consensus.

Risk of bias {#s2_3}
------------

The risk of bias was assessed by reviewers independently using a modified Ottawa classification for observational studies \[[@R42]\]. Any disagreements were resolved by consensus.

Statistical analysis {#s2_4}
--------------------

The responses were estimated according to Response Evaluation Criteria in Solid Tumors, including complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Patients with CR and PR were categorized as the responder group, and patients with SD and PD were categorized as the non-responder group. Toxicities were defined as all adverse effects that occurred after treatment with chemotherapy and/or radiotherapy. ORs with 95% CIs were used to evaluate the association between *GSTP1* and tumour response and toxicities based on raw data. Cox proportional HRs and 95% CIs for OS were also calculated using the most adjusted HR in each study. In this meta-analysis, we examined the association of variant genotypes of *GSTP1* polymorphism with treatment outcome and toxicities.

The heterogeneity was assessed using the *Q* test with a significance level of *P* \< 0.05. The *I*^2^ statistic was used to test the heterogeneity among the included studies \[[@R43]\]. A fixed-effect model (Mantel-Haenszel method) was applied if heterogeneity was not significant \[[@R44]\]. Otherwise, a random effect model (DerSimonian and Laird method) was utilized \[[@R45]\].

Subgroup analysis was carried out based on ethnicity, sample size, and therapeutic method. Ethnic subgroups consisted of three groups: East Asian (Chinese and Japanese), South Asian (Indian and Bangladeshi), and mixed descent (American, Canadian, and Brazilian). Sample size was divided into a large group (≥ 100 cases) and a small group (\< 100 cases). Therapeutic methods included chemotherapy ± surgery, radiotherapy ± surgery, and chemotherapy + radiotherapy ± surgery. Potential publication bias was assessed using a Funnel plot \[[@R46]\] and Egger\'s test \[[@R47]\]. Statistical analyses were conducted with STATA version 11.0 (Stata Corporation, College Station, Texas, USA). All *P* values were 2-sided and *P* \< 0.05 was considered statistically significant.

RESULTS {#s3}
=======

Study characteristics {#s3_1}
---------------------

A total of 831 potentially relevant publications were systematically identified. Of them, 784 studies were excluded because they were reviews, letters, comments, or irrelevant studies. An additional study was excluded because data were not provided, and the authors could not be reached \[[@R11]\]. Another study was excluded because it regarded progression-free survival as an observation endpoint \[[@R12]\]. One study was excluded because it regarded CR + PR + SD as the responder group \[[@R13]\]. Another study was excluded owing to inclusion of familial breast cancer and sporadic breast cancer patients \[[@R14]\]. Furthermore, as one study used three different regimens of chemotherapy, it was treated as three articles \[[@R15]\]. After applying the exclusion criteria, 31 studies with a total of 7506 patients were included \[[@R14]--[@R41]\]. The study selection flowchart is summarized in Figure [1](#F1){ref-type="fig"}. The basic characteristics of all included studies are listed in Table [1](#T1){ref-type="table"}. Sample sizes ranged from 40 to 1034 patients. Among the studies analysed, 15 reported tumour response events \[[@R15], [@R20]--[@R23], [@R26], [@R27], [@R31]--[@R35], [@R37], [@R38], [@R41]\], 13 reported OS \[[@R14], [@R17], [@R19], [@R23], [@R28], [@R29], [@R31]--[@R34], [@R38], [@R41]\], and 12 reported toxicities \[[@R16], [@R18], [@R24], [@R26], [@R27], [@R29], [@R30], [@R35]--[@R37], [@R39], [@R40]\]. Table [2](#T2){ref-type="table"} shows the quality indicators of the included studies.

![The flowchart of this meta-analysis](oncotarget-08-72939-g001){#F1}

###### Characteristics of all included studies in this meta-analysis

  Study                           Country      Publication   Genotyping method   Number of patient   Treatment                                                 toxicities                                Median follow-up   specimen
  ------------------------------- ------------ ------------- ------------------- ------------------- --------------------------------------------------------- ----------------------------------------- ------------------ ----------------------
  Sweeney, et al. \[[@R17]\]      America      2000          PCR-RFLP            240                 chemotherapy + radiotherapy, chemotherapy, radiotherapy   NP                                        58 months          tissue
  Yang, et al. \[[@R29]\]         China        2005          Multiplex PCR       1034                chemotherapy                                              NP                                        5.3 years          blood
  Ambrosone, et al. \[[@R16]\]    German       2006          Multiplex PCR       446                 radiotherapy after surgery                                skin toxicities                           NP                 blood
  Zárate, et al. \[[@R39]\]       Spain        2007          PCR-RFLP            94                  chemotherapy                                              haematological and non-haematological     NP                 blood
  Syamala, et al. \[[@R14]\]      India        2008          PCR                 347                 NP                                                        NP                                        NP                 blood
  Kuptsova, et al. \[[@R18]\]     German       2008          Multiplex PCR       390                 radiotherapy after surgery                                telangiectasia                            4.1 years          blood
  Bewick, et al. \[[@R19]\]       Canada       2008          PCR                 95                  chemotherapy                                              NP                                        10.4 months        blood or bone marrow
  Tang, et al. \[[@R20]\]         China        2009          PCR                 126                 chemotherapy                                              NP                                        6 weeks            blood
  Oliveira, et al. \[[@R21]\]     Brazil       2010          PCR-RFLP            40                  chemotherapy                                              NP                                        NP                 blood
  Yao, et al. \[[@R40]\]          America      2010          PCR-RFLP            458                 chemotherapy                                              hematologic                               10.8 years         tumor cell
  Zhong, et al. \[[@R22]\]        China        2010          PCR                 132                 chemotherapy                                              NP                                        9 weeks            blood
  Zhang (1), et al. \[[@R37]\]    China        2011          PCR-RFLP            120                 chemotherapy                                              hematologic                               NP                 blood
  Bai, et al. \[[@R23]\]          China        2012          PCR-RFLP            159                 chemotherapy                                              NP                                        4 years            blood
  Terrazzino, et al. \[[@R24]\]   Italy        2012          PCR                 237                 radiotherapy                                              skin fibrosis                             63 days            blood
  Raabe, et al. \[[@R25]\]        German       2012          PCR-RFLP            83                  radiotherapy                                              erythema                                  NP                 blood
  Ji, et al. \[[@R26]\]           China        2012          PCR                 153                 chemotherapy                                              neutropenia                               51 months          blood
  Tulsyan, et al. \[[@R27]\]      India        2013          PCR-RFLP            100                 chemotherapy                                              hematologic                               NP                 blood
  Duggan, et al. \[[@R28]\]       America      2013          PCR                 533                 surgery, surgery and radiotherapy, and chemotherapy       NP                                        11.29 years        blood
  Zhang (2), et al. \[[@R38]\]    China        2013          PCR-CTPP            219                 chemotherapy                                              NP                                        4 years            blood
  Zhao, et al. \[[@R15]\]         China        2014          PCR                 252                 chemotherapy                                              hematologic                               NP                 blood
  Sugishita, et al. \[[@R30]\]    Japan        2014          PCR                 102                 chemotherapy                                              hematologic                               967 days           blood
  Liu, et al. \[[@R34]\]          China        2014          PCR                 382                 chemotherapy after surgery                                NP                                        NP                 blood
  Zhou, et al. \[[@R31]\]         China        2015          PCR                 420                 chemotherapy after surgery                                NP                                        5 years            blood
  Wang (1), et al. \[[@R32]\]     China        2015          PCR-RFLP            310                 chemotherapy                                              NP                                        5 years            blood
  Wang (2), et al. \[[@R33]\]     China        2015          PCR-RFLP            262                 chemotherapy                                              NP                                        NP                 blood
  Islam, et al. \[[@R35]\]        Bangladesh   2015          PCR-RFLP            256                 chemotherapy                                              hematologic                               NP                 blood
  Eckhoff, et al. \[[@R36]\]      Denmark      2015          PCR                 150                 chemotherapy                                              docetaxel-induced peripheral neuropathy   7.5 months         blood
  Yuan, et al. \[[@R41]\]         China        2015          PCR-RFLP            273                 chemotherapy                                              NP                                        5 years            blood

*PCR* polymerase chain reaction, *NP* not provided

###### Quality assessment (risk of bias) of the included studies

  Study                           Ascertainment of outcome                          Adjusting for confounders   Attrition bias      Patient selection
  ------------------------------- ------------------------------------------------- --------------------------- ------------------- -----------------------------------
  Sweeney, et al. \[[@R17]\]      Main confounders and any additional confounders   Yes                         No risk             Consecutive
  Yang, et al. \[[@R29]\]         Main confounders and any additional confounders   Yes                         No risk             Consecutive
  Ambrosone, et al. \[[@R16]\]    Main confounders and any additional confounders   No                          No risk             Consecutive
  Zárate, et al. \[[@R39]\]       Main confounders and any additional confounders   No                          No risk             Selected/non-consecutive patients
  Syamala, et al. \[[@R14]\]      Main confounders and any additional confounders   No                          Unclear reporting   Selected/non-consecutive patients
  Kuptsova, et al. \[[@R18]\]     Main confounders and any additional confounders   No                          No risk             Consecutive
  Bewick, et al. \[[@R19]\]       Main confounders and any additional confounders   Yes                         No risk             Selected/non-consecutive patients
  Tang, et al. \[[@R20]\]         Main confounders and any additional confounders   No                          Unclear reporting   Consecutive
  Oliveira, et al. \[[@R21]\]     Main confounders and any additional confounders   No                          Unclear reporting   Consecutive
  Yao, et al. \[[@R40]\]          Main confounders and any additional confounders   No                          No risk             Consecutive
  Zhong, et al. \[[@R22]\]        Main confounders and any additional confounders   No                          Unclear reporting   Consecutive
  Zhang (1), et al. \[[@R37]\]    Main confounders and any additional confounders   No                          Unclear reporting   Selected/non-consecutive patients
  Bai, et al. \[[@R23]\]          Main confounders and any additional confounders   Yes                         No risk             Consecutive
  Terrazzino, et al. \[[@R24]\]   Main confounders and any additional confounders   No                          No risk             Consecutive
  Raabe, et al. \[[@R25]\]        Main confounders and any additional confounders   No                          Unclear reporting   Consecutive
  Ji, et al. \[[@R26]\]           Main confounders and any additional confounders   No                          Unclear reporting   Selected/non-consecutive patients
  Tulsyan, et al. \[[@R27]\]      Main confounders and any additional confounders   No                          Unclear reporting   Consecutive
  Duggan, et al. \[[@R28]\]       Main confounders and any additional confounders   Yes                         No risk             Consecutive
  Zhang (2), et al. \[[@R38]\]    Main confounders and any additional confounders   Yes                         No risk             Consecutive
  Zhao, et al. \[[@R15]\]         Main confounders and any additional confounders   No                          Unclear reporting   Consecutive
  Sugishita, et al. \[[@R30]\]    Main confounders and any additional confounders   No                          Unclear reporting   Selected/non-consecutive patients
  Liu, et al. \[[@R34]\]          Main confounders and any additional confounders   Yes                         No risk             Consecutive
  Zhou, et al. \[[@R31]\]         Main confounders and any additional confounders   Yes                         No risk             Consecutive
  Wang (1), et al. \[[@R32]\]     Main confounders and any additional confounders   Yes                         No risk             Consecutive
  Wang (2), et al. \[[@R33]\]     Main confounders and any additional confounders   No                          No risk             Selected/non-consecutive patients
  Islam, et al. \[[@R35]\]        Main confounders and any additional confounders   No                          Unclear reporting   Consecutive
  Eckhoff, et al. \[[@R36]\]      Main confounders and any additional confounders   No                          Unclear reporting   Consecutive
  Yuan, et al. \[[@R41]\]         Main confounders and any additional confounders   Yes                         No risk             Consecutive

Quantitative synthesis {#s3_2}
----------------------

Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"} summarize the meta-analyses of the association of the *GSTP1* polymorphism with tumour response, OS, and toxicities, respectively. The meta-analysis was conducted using a fixed-effect model when *P* \> 0.05 for the Q test, which indicated a lack of heterogeneity among studies; otherwise, a random-effect model was used.

###### Summary of results in the association of GSTP1 polymorphism with tumor response and overall survival

  GSTP1 Genotype                                                  No. of studies   Tumor response      No. of studies      Overall survival                                                                                              
  --------------------------------- --------------- ------------- ---------------- ------------------- ------------------- ------------------ ------- ------ ------------------- ------------------- ------------------- ------- ------- ------
  GA vs. AA                         Overall                       15               2941                1.32 (0.97--1.80)   0.073              0.001   63.2   13                  4274                1.14 (0.97--1.33)   0.106   0.328   11.7
  Ethnicity                         East Asian      12            2684             1.38 (0.99--1.92)   0.058               0.001              64.6    8      3059                1.10 (0.90--1.33)   0.347               0.289   17.9    
                                    South Asian     2             217              1.43 (0.46--4.43)   0.533               0.054              73.1    2      347                 1.53 (0.78--2.99)   0.218               0.739   0.0     
                                    Mixed descent   1             40               0.38 (0.10--1.15)   0.158               NA                 NA      3      868                 1.19 (0.78--1.81)   0.423               0.132   50.6    
  Sample size                       Large           14            2901             1.38 (1.02--1.88)   0.038               0.001              63.1    12     4179                1.11 (0.94--1.31)   0.231               0.306   14.1    
                                    Small           1             40               0.38 (0.10--1.45)   0.143               NA                 NA      1      95                  1.37 (0.88--2.13)   0.163               NA      NA      
  Overall                                           14            2901             1.29 (0.79--2.13)   0.312               0.000              71.6    12     4149                0.94 (0.56--1.57)   0.814               0.000   80.3    
  Ethnicity                         East Asian      12            2684             1.19 (0.69--2.03)   0.531               0.000              73.7    8      3059                1.08 (0.57--2.06)   0.806               0.000   85.7    
  GG vs. AA                                         South Asian   2                217                 2.41 (0.88--6.58)   0.086              0.467   0.0    1                   222                 0.30 (0.03--2.99)   0.305   NA      NA
  Mixed descent                     NA              NA            NA               NA                  NA                  NA                 3       868    0.72 (0.26--2.00)   0.525               0.052               66.2            
  GA + GG vs. AA (dominant model)   Sample size     Large         14               2901                1.29 (0.79--2.13)   0.312              0.000   71.6   11                  4054                0.89 (0.51--1.57)   0.692   0.000   81.6
                                    Small           NA            NA               NA                  NA                  NA                 NA      1      95                  1.51 (0.75--3.02)   0.246               NA      NA      
  Overall                                           15            2941             1.37 (0.97--1.94)   0.074               0.000              76.3    3      1048                1.74 (1.32--2.30)   \< 0.001            0.140   49.2    
  Ethnicity                         East Asian      12            2684             1.43 (0.97--2.10)   0.068               0.000              78.6    1      420                 2.53 (1.60--4.03)   NA                  NA      NA      
                                    South Asian     2             217              1.58 (0.55--4.56)   0.399               0.056              72.6    NA     NA                  NA                  NA                  NA      NA      
                                    Mixed descent   1             40               0.38 (0.10--1.15)   0.158               NA                 NA      2      628                 1.41 (0.99--2.00)   0.053               0.956   0.0     
  Sample size                       Large           14            2901             1.45 (1.02--2.06)   0.040               0.000              77.0    2      953                 1.98 (1.14--3.45)   0.015               0.152   51.2    
                                    Small           1             40               0.38 (0.10--1.45)   0.143               NA                 NA      1      95                  1.40 (0.92--2.12)   0.100               NA      NA      
  GG vs. AA+GA (recessive model)    Overall                       14               2901                1.05 (0.70--1.57)   0.829              0.000   66.2   NA                  NA                  NA                  NA      NA      NA
  Ethnicity                         East Asian      12            2684             0.97 (0.63--1.48)   0.872               0.000              68.7    NA     NA                  NA                  NA                  NA      NA      
                                    South Asian     2             217              2.07 (0.78--5.47)   0.143               0.797              0       NA     NA                  NA                  NA                  NA      NA      
                                    Mixed descent   NA            NA               NA                  NA                  NA                 NA      NA     NA                  NA                  NA                  NA      NA      
  Sample size                       Large           14            2901             1.05 (0.70--1.57)   0.829               0.000              66.2    NA     NA                  NA                  NA                  NA      NA      
                                    Small           NA            NA               NA                  NA                  NA                 NA      NA     NA                  NA                  NA                  NA      NA      
  Allele model (G vs. A)            Overall                       15               2941                1.26 (0.93--1.70)   0.134              0.000   82.2   2                   601                 1.32 (0.47--3.74)   0.601   0.004   87.7
  Ethnicity                         East Asian      12            2684             1.28 (0.91--1.79)   0.156               0.000              84.6    2      601                 1.32 (0.47--3.74)   0.601               0.004   87.7    
                                    South Asian     2             217              1.54 (0.76--3.10)   0.231               0.101              62.9    NA     NA                  NA                  NA                  NA      NA      
                                    Mixed descent   1             40               0.38 (0.10--1.45)   0.143               NA                 NA      NA     NA                  NA                  NA                  NA      NA      
  Sample size                       Large           14            2901             1.31 (0.96--1.78)   0.089               0.000              83.1    2      601                 1.32 (0.47--3.74)   0.601               0.004   87.7    
                                    Small           1             40               0.38 (0.10--1.45)   0.143               NA                 NA      NA     NA                  NA                  NA                  NA      NA      

*GSTP1* glutathione S-transferase P1, OR odds ratio, CI confidence interval, HR hazard ratio, NA not available.

###### Summary of results in the association of *GSTP1* polymorphism with toxicities

  GSTP1 Genotype                                                        No. of studies   toxicities                                                      
  --------------------------------- ------------------------ ---------- ---------------- ----------------------- ----------------------- ------- ------- ------
  GA vs. AA                                                   Overall   11               1950                    **1.45 (1.04--2.01)**   0.028   0.024   51.5
  Therapeutic method                Chemotherapy ± surgery   8          1031             **1.64 (1.05--2.56)**   0.030                   0.032   54.2    
                                    Radiotherapy ± surgery   3          919              1.10 (0.79--1.52)       0.579                   0.144   48.5    
  GG vs. AA                                                   Overall   11               1950                    **1.47 (1.03--2.10)**   0.036   0.709   0.0
  Therapeutic method                Chemotherapy ± surgery   8          1031             1.58 (0.98--2.55)       0.059                   0.776   0.0     
                                    Radiotherapy ± surgery   3          919              1.33 (0.77--2.28)       0.306                   0.207   36.4    
  GA + GG vs. AA (dominant model)                             Overall   14               2747                    1.35 (0.99--1.83)       0.058   0.001   61.3
  Therapeutic method                Chemotherapy ± surgery   10         1591             1.40 (0.90--2.18)       0.133                   0.001   68.8    
                                    Radiotherapy ± surgery   4          1156             1.24 (0.93--1.65)       0.143                   0.213   33.3    
  GG vs. AA+GA (recessive model)                              Overall   12               2044                    **1.54 (1.13--2.09)**   0.006   0.330   11.8
  Therapeutic method                Chemotherapy ± surgery   9          1125             **1.72 (1.17--2.54)**   0.006                   0.526   0.0     
                                    Radiotherapy ± surgery   3          919              1.12 (0.47--2.67)       0.792                   0.092   58.2    
  G vs. A (Allele model)                                      Overall   11               1950                    **1.35 (1.07--1.71)**   0.011   0.023   51.6
  Therapeutic method                Chemotherapy ± surgery   8          1031             **1.57 (1.11--2.21)**   0.010                   0.013   60.7    
                                    Radiotherapy ± surgery   3          919              1.12 (0.89--1.40)       0.346                   0.568   0.0     

*GSTP1* glutathione S-transferase P1, OR odds ratio, CI confidence interval, NA not available.

Tumor response {#s3_3}
--------------

There was no significant association between the *GSTP1* polymorphism and tumour response (GA *vs.* AA OR = 1.32, 95% CI 0.97--1.80, *P* = 0.073, Figure [2](#F2){ref-type="fig"}; GG *vs.* AA OR = 1.29, 95% CI 0.79--2.13, *P* = 0.312; dominant model OR = 1.37, 95% CI 0.97--1.94, *P* = 0.074; recessive model OR = 1.05, 95% CI 0.70--1.57, *P* = 0.829; or allele model OR = 1.26, 95% CI 0.93--1.70, *P* = 0.134). Publication bias was observed in the Funnel plot and Egger\'s test (GG *vs.* AA, *P* = 0.023; and recessive model, *P* = 0.034), but not for other models (GA *vs.* AA, *P* = 0.066, Figure [3](#F3){ref-type="fig"}; dominant model *P* = 0.052, or allele model *P* = 0.054).

![Forest plot of tumor response for *GSTP1* gene polymorphism in breast cancer patients (GA *vs*. AA)](oncotarget-08-72939-g002){#F2}

![Funnel plot of *GSTP1* gene polymorphism for assessment of publication bias: tumor response (GA *vs*. AA)](oncotarget-08-72939-g003){#F3}

Overall survival {#s3_4}
----------------

The *GSTP1* polymorphism was associated with OS in the dominant genetic model (HR = 1.74, 95% CI 1.32--2.30, *P \<* 0.001), but not other genetic models (GA *vs.* AA, HR = 1.14, 95% CI 0.97--1.33, *P* = 0.106; GG *vs.* AA, HR = 0.94, 95% CI 0.56--1.57, *P* = 0.814; or allele model HR = 1.32, 95 % CI 0.47--3.74, *P* = 0.601), as shown in Table [3](#T3){ref-type="table"}. Publication bias was not observed in the Funnel plot or Egger\'s test (GA *vs.* AA, *P* = 0.365; and GG *vs.* AA, *P* = 0.719).

Toxicities {#s3_5}
----------

Pooled results showed that there was a significant increase of toxicities (GA *vs.* AA OR = 1.45, 95% CI 1.04--2.01, *P* = 0.028, Figure [4A](#F4){ref-type="fig"}; GG *vs.* AA OR = 1.47, 95% CI 1.03--2.10, *P* = 0.036, Figure [4B](#F4){ref-type="fig"}; recessive model OR = 1.54, 95% CI 1.13--2.09, *P* = 0.006, Figure [4C](#F4){ref-type="fig"}; and allele model OR = 1.35, 95% CI 1.07--1.71, *P* = 0.011, Figure [4D](#F4){ref-type="fig"}; Table [4](#T4){ref-type="table"}). The dominant model was not found to be significantly associated with toxicity (OR = 1.35, 95% CI 0.99--1.83, *P* = 0.058). Publication bias was observed in the Funnel plot and Egger\'s test for the genetic models (GA *vs.* AA, *P* = 0.008; dominant model, *P* = 0.011; and allele model, *P* = 0.008) There was no publication bias in other models (GG *vs.* AA, *P* = 0.271; and the recessive model, *P* = 0.957).

![Forest plot of toxicities for *GSTP1* gene polymorphism in breast cancer patients ((**A)**: GA *vs.* AA; (**B**): GG *vs.* AA; (**C**): recessive model; (**D**): allele model).](oncotarget-08-72939-g004){#F4}

Subgroup analysis {#s3_6}
-----------------

In subgroup analyses, the *GSTP1* polymorphism was associated with increased tumour response when the sample size was large (GA *vs.* AA OR = 1.38, 95% CI 1.02--1.88, *P* = 0.038; and dominant model OR = 1.45, 95% CI 1.02--2.06, *P* = 0.829), but this association was not found when the sample size was small, or with any ethnicity subgroup. In addition, no associations between *GSTP1* polymorphism and OS were found in either large or small sample sizes. The estimated results showed that there was an increased incidence of toxicities after chemotherapy ± surgery in three genetic models: GA *vs.* AA (OR = 1.64, 95% CI 1.05--2.56, *P* = 0.030), recessive model (OR = 1.72, 95% CI 1.17--2.54, *P* = 0.006), and allele model (OR = 1.57, 95% CI 1.11--2.21, *P* = 0.010; Table [4](#T4){ref-type="table"}). However, we failed to find such an association in the radiotherapy ± surgery group.

DISCUSSION {#s4}
==========

While the breast cancer treatment response of chemotherapy and/or radiotherapy cannot be optimally predicted, the consequence of gene polymorphism affecting drug efficacy, through encoding metabolizing enzymes and drug transporters, has been confirmed \[[@R48]\]. For breast cancer, anthracycline/paclitaxel-based agents are often effective, which is due to DNA damage, as well as mitochondrial membrane disruption, triggering the apoptotic mechanism and contributing to tumour cell death by the generation of reactive oxygen species (ROS). GSTs (particularly GSTP1) are multifunctional enzymes involved in the protection of cellular components targeted by anticancer drugs. GSTs detoxify chemotherapeutic drugs, or their metabolites, by catalysing the reduction of these compounds through conjugation with glutathione \[[@R49]\]. Therefore, this function of GSTs may result in tumour resistance to cytotoxic agents during chemotherapy \[[@R50]\]. However, the substitution of Ile to Val at codon 105 would result in the decrease of this function, and thus potentially cause an increase in the efficacy of chemotherapy \[[@R10]\]. Previous studies have investigated the association between the *GSTP1* polymorphism and treatment outcomes in other cancers \[[@R52]--[@R53]\]. In these studies, no significant association between the *GSTP1* polymorphism and tumour response from platinum-based chemotherapy was found in either colorectal cancer or gastric cancer \[[@R51], [@R52]\]. On the contrary, the variant G *allele* was significantly associated with positive response to platinum-based chemotherapy in East-Asian patients with non-small cell lung cancer \[[@R53]\]. A significantly longer OS was observed in GG + GA genotypes than in AA genotypes in gastric cancer \[[@R52]\]. In the current meta-analysis, there was no significant association between the *GSTP1* polymorphism and tumour response. With these inconsistent results, additional studies using uniform evaluation standards are needed in future to sufficiently determine the association between the *GSTP1* polymorphism and tumour response.

Chemotherapy and radiotherapy can potentially be interrupted by treatment toxicities. Radiotherapy often has short-term toxicities such as skin erythema and irritation, as well as medium- and long-term toxicities such as breast oedema, pain, fibrosis, and/or telangiectasia. Chemotherapy is usually accompanied by toxicities, such as hematologic, cardiac, and hepatic dysfunction, and vomiting. Severe toxicities might result in treatment interruption and thereby affect treatment efficacy. The *GSTP1* Ile to Val substitution has been associated with reduced enzyme activity in the removal of chemotherapy agents \[[@R3]\]. Therefore, it may lead to several toxicities during chemotherapy. Two previous studies have evaluated the association between the *GSTP1* polymorphism and toxicities. Both studies found that patients with the AA genotype were at significantly higher risk of haematological and neurological toxicities, compared with patients expressing the AG or GG genotypes \[[@R54], [@R55]\]. In the current study, we found that the G*STP1* polymorphism was associated with increased toxicities, especially in patients treated with chemotherapy ± surgery. However, this function is advantageous for decreasing toxicities of patients receiving radiotherapy ± surgery. As radiation results in the generation of ROS and lipid peroxidation, nuclear *GSTP1* plays a direct role in the cellular sensitivity to oxidative stress. This oxidative stress is caused by hydrogen peroxide through the formation of lipid-peroxide modified DNA. In this meta-analysis, no association was observed between the *GSTP1* polymorphism and toxicities due to radiotherapy ± surgery.

Although an effort was made to conduct an accurate and comprehensive analysis, this study has several limitations. First, some factors that may lead to heterogeneity and thus have an influence on treatment outcome---such as treatment options (adjuvant and/or neoadjuvant chemotherapy), chemotherapeutic agents, breast cancer subtypes (hormone receptor-positive, Her2-positive, and triple-negative), and TNM staging status---were not strictly described in some studies. Therefore, these factors could not be stratified into subgroups with great detail. Furthermore, the major sources of heterogeneity where not detected, except for subgroup analysis by ethnicity, sample size, and therapeutic method. Second, publication bias existed in this meta-analysis. This may be due to the absence of some negative trials, which may lead to overestimate the treatment effects.

In conclusion, our meta-analysis suggests that *GSTP1* polymorphism may be associated with increased incidence of toxicities, especially in patients treated with chemotherapy ± surgery. Nevertheless, no significant associations were found between the *GSTP1* polymorphism and tumour response or OS.
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